News

HER2-targeted therapy shows antitumor activity in metastatic colorectal cancer

Trastuzumab deruxtecan demonstrated durable benefit among patients with HER2-expressing metastatic colorectal cancer, according to findings of the phase 2 DESTINY-CRC01 study presented during the ASCO20 Virtual Scientific Program.Interstitial lung disease appeared to be an important risk that requires careful recognition and intervention, researchers noted.“Trastuzumab deruxtecan [Enhertu; AstraZeneca, Daiichi Sankyo] is a novel antibody-drug conjugate composed…

News

HER2-targeted therapy shows antitumor activity in metastatic colorectal cancer

Trastuzumab deruxtecan demonstrated durable benefit among patients with HER2-expressing metastatic colorectal cancer, according to findings of the phase 2 DESTINY-CRC01 study presented during the ASCO20 Virtual Scientific Program.Interstitial lung disease appeared to be an important risk that requires careful recognition and intervention, researchers noted.“Trastuzumab deruxtecan [Enhertu; AstraZeneca, Daiichi Sankyo] is a novel antibody-drug conjugate composed…

News

AGA announces awardees to receive research funding

The American Gastroenterological Association announced the 17 researchers who will receive funding through the AGA Research Foundation Awards program, according to a press release.The 2020 awards will offer $2.2 million in research funding to support investigators’ work that will enhance the understanding of gastrointestinal and liver conditions and lead to better treatment options for patients…

News

AGA announces awardees to receive research funding

The American Gastroenterological Association announced the 17 researchers who will receive funding through the AGA Research Foundation Awards program, according to a press release.The 2020 awards will offer $2.2 million in research funding to support investigators’ work that will enhance the understanding of gastrointestinal and liver conditions and lead to better treatment options for patients…

News

PAMORAs help achieve response in opioid-induced constipation

Peripherally acting mu-opioid receptor antagonists helped patients with opioid-induced constipation achieve therapeutic response, according to a meta-analysis published in Alimentary Pharmacology & Therapeutics.Michael Camilleri, MD, from Mayo Clinic in Rochester, Minnesota, and colleagues wrote that opioid-induced constipation can decrease treatment satisfaction and can lead patients to discontinue opioid therapy.“Mu-opioid receptors are expressed on enteric nerve…

News

PAMORAs help achieve response in opioid-induced constipation

Peripherally acting mu-opioid receptor antagonists helped patients with opioid-induced constipation achieve therapeutic response, according to a meta-analysis published in Alimentary Pharmacology & Therapeutics.Michael Camilleri, MD, from Mayo Clinic in Rochester, Minnesota, and colleagues wrote that opioid-induced constipation can decrease treatment satisfaction and can lead patients to discontinue opioid therapy.“Mu-opioid receptors are expressed on enteric nerve…

News

Pembrolizumab doubles PFS for certain patients with metastatic colorectal cancer

First-line pembrolizumab extended PFS vs. chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to findings to be presented during the ASCO20 Virtual Scientific Program.The agent also appeared associated with fewer treatment-related adverse events.“Pembrolizumab should be considered a new standard of care for these patients,” Thierry André, MD, professor of medical oncology at…

News

Pembrolizumab doubles PFS for certain patients with metastatic colorectal cancer

First-line pembrolizumab extended PFS vs. chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to findings to be presented during the ASCO20 Virtual Scientific Program.The agent also appeared associated with fewer treatment-related adverse events.“Pembrolizumab should be considered a new standard of care for these patients,” Thierry André, MD, professor of medical oncology at…